{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T13:16:47Z","timestamp":1760707007397,"version":"build-2065373602"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2002,7,23]],"date-time":"2002-07-23T00:00:00Z","timestamp":1027382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>PURPOSE<\/jats:title><jats:p>To evaluate the efficacy and side effects of psolaren with ultraviolet light A (PUVA) and interferon\u2010alpha\u20102a (IFN\u2010\u03b1\u20102a) in patients with mycosis fungoides (MF) and S\u00e9zary syndrome (SS).<\/jats:p><\/jats:sec><jats:sec><jats:title>PATIENTS AND METHODS<\/jats:title><jats:p>From May 1993 to January 1999, 63 symptomatic patients with all stages of MF and SS were treated in a prospective Phase II trial with systemic escalating doses of IFN\u2010\u03b1\u20102a combined with PUVA for 1 year, followed by indefinite PUVA maintenance in complete responding patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Sixty\u2010three patients were enrolled (Stage IA, <jats:italic>n<\/jats:italic> = 6; IB, <jats:italic>n<\/jats:italic> = 37; IIA, <jats:italic>n<\/jats:italic> = 3; IIB, <jats:italic>n<\/jats:italic> = 3; III, <jats:italic>n<\/jats:italic> = 12; IVA, <jats:italic>n<\/jats:italic> = 2). Ten patients had received previous therapy. The median follow\u2010up duration for the entire cohort is 37 months. Of 63 patients, 51 achieved a complete response (CR; 74.6%) or partial response (PR; 6%) to therapy. The median response duration is 32 months. The 5\u2010year overall survival rate is 91% and the 5\u2010year disease\u2010free survival rate is 75%. No life\u2010threatening side effects were observed. Five patients stopped IFN\u2010\u03b1\u20102a therapy due to toxicity. Eighty\u2010four percent of the patients received more than 75% of the planned dose (12 million units three times a week).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>This combination of IFN\u2010\u03b1\u20102a and phototherapy is an effective and safe therapy for patients with symptomatic MF. Cancer 2002;95:569\u201375. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10706<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10706","type":"journal-article","created":{"date-parts":[[2002,10,6]],"date-time":"2002-10-06T07:53:08Z","timestamp":1033890788000},"page":"569-575","source":"Crossref","is-referenced-by-count":81,"title":["Phase II trial of interferon\u2010\u03b1\u20102a plus psolaren with ultraviolet light A in patients with cutaneous T\u2010cell lymphoma"],"prefix":"10.1002","volume":"95","author":[{"given":"Vanna","family":"Chiarion\u2010Sileni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Bononi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cleto Veller","family":"Fornasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariella","family":"Soraru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Alaibac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eros","family":"Ferrazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Redelotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Peserico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Monfardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Salvagno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,7,23]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"131","article-title":"Cutaneous T cell lymphoma","volume":"1","author":"Murphy GF","year":"1988","journal-title":"Adv Pathol."},{"key":"e_1_2_6_3_2","first-page":"725","article-title":"Report of the committee on staging and classification of cutaneous t\u2010cell lymphomas","volume":"63","author":"Bunn PA","year":"1979","journal-title":"Cancer Treat Rep."},{"key":"e_1_2_6_4_2","first-page":"276","article-title":"Mycosis fungoides and the Sezary syndrome","volume":"26","author":"Kim YH","year":"1999","journal-title":"Semin Oncol."},{"key":"e_1_2_6_5_2","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1093\/annonc\/11.suppl_1.S11","article-title":"EORTC classification for primary cutaneous lymphoma: a comparison with the R.E.A.L. classification and the proposed WHO classification","volume":"11","author":"Willemze R","year":"2000","journal-title":"Ann Oncol."},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-6053(98)80031-8"},{"key":"e_1_2_6_7_2","first-page":"452","article-title":"Mycosis fungoides. Diagnosis and pathogenesis","volume":"30","author":"Barcos M","year":"1992","journal-title":"Haematopathology."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)70212-3"},{"key":"e_1_2_6_9_2","first-page":"31","article-title":"State of the art therapy of mycosis fungoides and S\u00e9zary syndrome","volume":"6","author":"Kemme DJ","year":"1992","journal-title":"Oncology."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(89)70051-7"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.8.949"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(87)70255-2"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12875523"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1985.tb02340.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(97)00127-2"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(90)70312-6"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1987.01660260071016"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70036-2"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V84.3.733.733","article-title":"2\u2010Clorodeoxyadenosine therapy in patients with T\u2010cell lymphoproliferative disorders","volume":"84","author":"O'Brien S","year":"1994","journal-title":"Blood."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/82.16.1353"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1200\/JCO.1993.11.9.1682","article-title":"Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T\u2010cell lymphoma","volume":"11","author":"Hesketh P","year":"1993","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860415)57:8 <1689::AID-CNCR2820571311>3.0.CO;2-M"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-101-4-484"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1993.tb01595.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30060-1"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/82.3.203"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.129.6.747"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.257"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12875523"},{"key":"e_1_2_6_30_2","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon \u03b1\u20102a plus acitretin versus interferon\u2010\u03b1\u20102a plus PUVA in patients with cutaneous T\u2010cell lymphoma stages I and II","volume":"10","author":"Stadler R","year":"1992","journal-title":"Blood."},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198702053160603"},{"key":"e_1_2_6_32_2","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1200\/JCO.2000.18.15.2908","article-title":"Primary cutaneous T\u2010cell lymphomas: review and current concepts","volume":"18","author":"Sieghel R","year":"2000","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198912283212603"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.4.1636.1636_1636_1642"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90119-X"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10706","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10706","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:20:26Z","timestamp":1760296826000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7,23]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,8]]}},"alternative-id":["10.1002\/cncr.10706"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10706","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2002,7,23]]}}}